RTP Mobile Logo

Friday, June 1, 2018, Chicago, IL, 7:00 PM – 9:00 PM

Cases from the Community: Clinical Investigators Provide Their Perspectives on Emerging Research and Actual Patients with Non-Small Cell Lung Cancer

Event Details

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

6:30 PM – 7:00 PM (Central Time) — Registration and Dinner Buffet
7:00 PM – 9:00 PM (Central Time) — Educational Meeting

Meeting Room:
Grand Ballroom (Level 2)

There is no registration fee for this event. However, preregistration is advised as seating is limited.  
Matthew D Hellmann, MD
Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, New York

Corey J Langer, MD
Director of Thoracic Oncology
Abramson Cancer Center
Professor of Medicine
Perelman School of Medicine
University of Pennsylvania
Vice Chair, Radiation Therapy Oncology Group
Philadelphia, Pennsylvania

Geoffrey R Oxnard, MD
Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Martin Reck, MD, PhD
Head of Department of Thoracic Oncology
Head of Clinical Trial Department
LungenClinic Grosshansdorf
Grosshansdorf, Germany

Alice Shaw, MD, PhD
Professor of Medicine
Harvard Medical School
Center for Thoracic Cancers
Massachusetts General Hospital
Boston, Massachusetts

Neil Love, MD
Research To Practice
Miami, Florida

Not an official event of the 2018 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or the Conquer Cancer Foundation.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Foundation Medicine, Genentech BioOncology, Merck and Takeda Oncology.


Meeting Format and Agenda

Prior to the event, RTP will video record several community-based medical oncologists presenting challenging non-small cell lung cancer (NSCLC) cases from their practices. To begin each meeting module, one or more of these recorded cases will be presented. Dr Love will then ask the faculty to provide their perspectives in an effort to demonstrate the optimal approach to patient care. After the case presentation(s) for each module, one of the faculty will deliver a short presentation on emerging research and ongoing trials related to a particular area of NSCLC management. Moderated panel discussion will follow to provide additional viewpoints on the information presented.

MODULE 1: Long-Term Management of NSCLC in Patients with an Activating EGFR Mutation — Dr Oxnard

  • Major efficacy and tolerability findings from FLAURA; recent FDA approval of osimertinib as first-line therapy
  • Management of CNS metastases in patients with EGFR mutations
  • Optimal treatment of disease that has progressed on first-line EGFR tyrosine kinase inhibitor therapy; incidence, clinical relevance and spectrum of resistance mechanisms in patients experiencing progression on osimertinib
  • Sequencing immune checkpoint inhibitors for patients with metastatic NSCLC and a documented EGFR mutation or other genomic alteration

MODULE 2: Recent Treatment Advances for Patients with ALK/ROS1- and BRAF-Positive NSCLC; Other Targets with the Potential to Affect Treatment Decision-Making — Dr Shaw

  • Disease-related factors influencing the selection of first- and later-line therapy for patients with ALK-positive disease
  • Design, available data and clinical implications of the ALEX and J-ALEX (alectinib) and ASCEND-4 (ceritinib) trial results on first-line decision-making for patients with ALK-positive metastatic NSCLC
  • Published efficacy and safety data with and FDA approval of brigatinib in patients with crizotinib-refractory disease
  • Incidence, identification and prognostic implications of a BRAF V600E mutation
  • Other identifiable genomic alterations (eg, RET, MET, HER2, NTRK)

MODULE 3: Optimal Integration of Immune Checkpoint Inhibition into Clinical Decision-Making for Patients with Locally Advanced NSCLC — Dr Reck

  • Potential synergy between radiation therapy and immune checkpoint inhibitors
  • Design, eligibility criteria and major efficacy and safety findings from the Phase III PACIFIC trial
  • Incidence and severity of toxicities observed in patients receiving sequential durvalumab
  • FDA approval and patient selection for durvalumab in the management of Stage III NSCLC; impact of radiation therapy side effects, actionable tumor mutations and other clinical factors on the decision to use durvalumab
  • Ongoing clinical trials evaluating the potential contribution of immune checkpoint inhibitors for patients with locally advanced disease

MODULE 4: Current Role of Immune Checkpoint Inhibitors in Combination with Chemotherapy and/or Anti-angiogenic Agents in the Treatment of Metastatic Disease — Dr Langer

  • Effect of PD-L1 tumor proportion score on responsiveness to anti-PD-1/PD-L1 therapy and implications for therapeutic selection; emerging results from the Phase III KEYNOTE-042 trial
  • Available data with, FDA approval of and patient selection for pembrolizumab in combination with carboplatin/pemetrexed as first-line therapy for patients with nonsquamous NSCLC
  • Major safety and efficacy findings from the Phase III IMpower150 study evaluating atezolizumab and bevacizumab in combination with carboplatin/paclitaxel in previously untreated advanced nonsquamous NSCLC
  • Design, eligibility criteria and potential implications of emerging results from the Phase III IMpower131 trial evaluating atezolizumab in combination with carboplatin/paclitaxel or carboplatin/nanoparticle albumin-bound (nab) paclitaxel as first-line therapy for patients with metastatic squamous cell NSCLC

MODULE 5: Potential Role of Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies in Combination; Future Directions for Clinical Research — Dr Hellmann

  • Safety and efficacy findings from the Phase III CheckMate-227 trial comparing nivolumab plus ipilimumab versus chemotherapy as first-line therapy for NSCLC in patients with high tumor mutational burden (TMB)
  • Potential role of TMB in NSCLC decision-making; other predictors of response to immune checkpoint inhibitors under investigation in lung cancer
  • Other ongoing trials evaluating anti-PD-1/PD-L1 and anti-CTLA-4 combinations for patients with NSCLC
  • Presence of prevalence of other inhibitory immune checkpoints (eg, LAG-3, TIM-3, KIR)
  • Available clinical trial data with and ongoing and planned studies of anti-PD-1/PD-L1 antibodies in the neoadjuvant and adjuvant settings

CE Information

Target Audience:
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of non-small cell lung cancer (NSCLC).

Learning Objectives and Goals:
At the conclusion of this activity, participants should be able to:

  • Appreciate available Phase III data documenting the benefit of sequential anti-PD-L1 therapy after completion of chemoradiation therapy for Stage III NSCLC, and consider the role of durvalumab for appropriate patients.
  • Recognize available and emerging research information validating the utility of diagnostic assays designed to measure EGFR, ALK, ROS1, BRAF and PD-L1 status, assess which testing platforms should be used and appropriately employ the results of these assessments to individualize first- and later-line therapy for patients with metastatic NSCLC.
  • Recall the results from the Phase III FLAURA trial and consider how, if at all, these findings and the subsequent FDA approval of osimertinib as first-line therapy affect current or future therapy for patients with EGFR mutations.
  • Communicate the efficacy and safety of approved and investigational ALK inhibitors to appropriate patients with NSCLC, considering the predictive utility of ALK mutation testing.
  • Review published research documenting the safety and efficacy of anti-PD-1/PD-L1 antibodies used as monotherapy or in combination with chemotherapy with or without anti-VEGF therapy for newly diagnosed metastatic NSCLC.
  • Consider available Phase III data comparing nivolumab in combination with ipilimumab to chemotherapy as first-line treatment for patients with NSCLC and a high tumor mutational burden.
  • Describe ongoing research to assist in the identification of additional biomarkers, tumor characteristics or other clinical features that are indicative of response to immune checkpoint inhibitors in patients with NSCLC.
  • Recall the design of ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies in combination with other immunotherapeutic and systemic therapies for NSCLC, and counsel appropriate patients about availability and participation.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Foundation Medicine, Genentech BioOncology, Merck and Takeda Oncology.


Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Meeting Room:
Grand Ballroom (Level 2)

The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center.



Thank you for your interest in our educational program.  At this time, online preregistration is closed. However, seats are still available for the conference. Onsite registration will be open starting at 6:30 PM (Central Time) on Friday, June 1st. If you are interested in attending, please visit our registration desk in the Grand Ballroom foyer located on the second level of the Hilton Chicago (720 Michigan Avenue, Chicago, IL).

Please note, onsite registrant seating will be prioritized for healthcare professionals directly involved in the treatment of patients. If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.